Indrayava: Traditional Uses, Evidence & Safety

TL;DR

Indrayava, the seeds of Holarrhena antidysenterica, is Ayurveda's seed drug for atisara (diarrhea/dysentery); the bark of the same plant is kutaja. Nearly all research is on the bark: an open 40-patient study reported 70% symptom improvement in amoebiasis/giardiasis, and a small series noted side effects (nausea, vertigo, low blood pressure). Seed-specific human data are essentially absent.

(58 words. Sources: IAMJ 2023 kutaja review; IJPP 1983 letter; traditional-use review.)

What it is

Indrayava (also called kutajabeeja or vatsakabeeja) are the seeds of Holarrhena antidysenterica (L.) Wall., a tree of the dogbane family (Apocynaceae). The same plant's stem bark is the drug kutaja: the better-known Ayurvedic remedy for dysentery. This distinction matters because almost all published research is on the bark, not the seeds. The bark and seeds are both used to treat amoebic dysentery and diarrhea in traditional accounts, and the seeds are described as cooling, appetizing, and astringent to the bowels (traditional-use review; kutaja review, IAMJ 2023). The plant's characteristic constituents are steroidal alkaloids, chiefly conessine, along with holarrhenine and kurchicine (traditional-use review).

Traditional use

Classical Ayurvedic texts (including the Bhavaprakasha tradition, as summarized in published reviews) record kutaja bark for atisara (diarrhea), raktatisara, and pravahika (dysentery), while the seeds, indrayava, are listed for kapha disorders, loss of appetite, dysuria, skin problems, piles, and as an astringent in bowel complaints (kutaja review, IAMJ 2023). These are traditional claims, not clinical proof.

What modern research says

Amoebiasis and giardiasis (bark; open-label, uncontrolled)

The most-cited human study used the bark, not the seeds: Singh (1985) reported an open clinical study of kutaja stem-bark extract in 40 patients with intestinal amoebiasis and giardiasis, with improvement in about 70% of clinical symptoms (loose motions, flatulence, abdominal cramping, mucus in stools) at 4 g/day in three divided doses for 15 consecutive days (kutaja review, IAMJ 2023). This was open-label with no control group: a weak design that cannot rule out natural recovery or placebo effects.

Seed-specific evidence

Human studies of the seeds specifically were not found. Laboratory work on seed and bark extracts has reported antibacterial activity against enteric bacteria in agar-diffusion assays: test-tube findings, not clinical evidence (seed-and-bark antimicrobial paper). Animal toxicology referenced in a published case report gives an LD50 greater than 3,000 mg/kg for the seed: a crude animal safety signal only (case report, J Diabetes Metab).

What the evidence does not support (yet)

No randomized, controlled human trial of indrayava (seeds) exists for dysentery, diarrhea, or any other condition. The amoebiasis data concern the bark and come from uncontrolled studies. Traditional seed uses remain untested in humans.

Dosage

No seed-specific clinical dose exists. The only human regimen on record is the bark study's: 4 g/day of kutaja bark in three divided doses for 15 days: an open-label research regimen for the bark, not the seeds, and not a recommendation (kutaja review, IAMJ 2023). Do not infer a seed dose from this article.

Safety & contraindications

A published letter in the Indian Journal of Physiology and Pharmacology reported side effects of kutaja bark powder in a small case series: of 11 indoor patients given 4 g/day for 15 days, four developed drug-attributed symptoms: including nausea, flatulence, agitation, vertigo, syncope, and, in one patient on 6 g/day, hypotension (blood pressure 66/40 mm Hg) (IJPP letter, 1981/83). The letter's authors concluded even "harmless-seeming" indigenous drugs can produce side effects. Whether the seeds share this profile is unstudied. Avoid during pregnancy and breastfeeding for lack of safety data, and do not use for dysentery without medical supervision: dysentery can be dangerous and needs proper diagnosis.

FAQs

What is indrayava?

Indrayava are the seeds of Holarrhena antidysenterica, the tree whose bark is the better-known Ayurvedic drug kutaja. Traditional texts list the seeds for bowel complaints, appetite loss, dysuria, and skin problems (kutaja review, IAMJ 2023).

Is indrayava the same as kutaja?

No. Both come from Holarrhena antidysenterica, but kutaja is the stem bark and indrayava is the seeds. Nearly all published research, including the amoebiasis clinical study, is on the bark.

Does indrayava work for dysentery or diarrhea?

There is no controlled human evidence for the seeds. An open, uncontrolled 40-patient study of the bark reported 70% symptom improvement in amoebiasis/giardiasis (kutaja review, IAMJ 2023): weak evidence that does not transfer to the seeds.

Is indrayava safe?

Seed-specific human safety data do not exist. The bark caused side effects (nausea, vertigo, fainting, low blood pressure) in a small published case series (IJPP letter, 1981/83). Avoid in pregnancy and breastfeeding, and seek medical care for dysentery rather than self-treating.

What is conessine?

Conessine is the principal steroidal alkaloid of Holarrhena antidysenterica, most studied in the bark; it has shown anti-amoebic and antiplasmodial activity in laboratory studies (kutaja review, IAMJ 2023).

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.